Drug Risks And Benefits Should Be Quantified For Public, Pfizer Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry will collaborate with FDA on ways to communicate risk/benefit information to patients, physicians and lawmakers, Pfizer Senior VP Corr says.